statistiche ricercatore

Continente	#
EU - Europa	630
NA - Nord America	589
AS - Asia	311
SA - Sud America	95
Continente sconosciuto - Info sul continente non disponibili	42
AF - Africa	8
OC - Oceania	1
Totale	1.676

Nazione	#
US - Stati Uniti d'America	569
RU - Federazione Russa	344
SG - Singapore	136
IT - Italia	91
IE - Irlanda	78
BR - Brasile	74
CN - Cina	64
SE - Svezia	45
HK - Hong Kong	35
DE - Germania	18
IN - India	15
BD - Bangladesh	14
VN - Vietnam	14
FR - Francia	11
CA - Canada	10
GB - Regno Unito	9
FI - Finlandia	7
NL - Olanda	7
JP - Giappone	5
LT - Lituania	5
TR - Turchia	5
VE - Venezuela	5
AR - Argentina	4
CO - Colombia	4
AT - Austria	3
EC - Ecuador	3
IL - Israele	3
MX - Messico	3
MY - Malesia	3
PH - Filippine	3
PL - Polonia	3
UA - Ucraina	3
ZA - Sudafrica	3
BH - Bahrain	2
EG - Egitto	2
ES - Italia	2
HN - Honduras	2
ID - Indonesia	2
IQ - Iraq	2
JM - Giamaica	2
OM - Oman	2
PE - Perù	2
PY - Paraguay	2
AU - Australia	1
BE - Belgio	1
CI - Costa d'Avorio	1
CL - Cile	1
CR - Costa Rica	1
DK - Danimarca	1
EU - Europa	1
GT - Guatemala	1
KE - Kenya	1
KG - Kirghizistan	1
KZ - Kazakistan	1
MK - Macedonia	1
MN - Mongolia	1
NI - Nicaragua	1
NP - Nepal	1
PK - Pakistan	1
SK - Slovacchia (Repubblica Slovacca)	1
TN - Tunisia	1
UZ - Uzbekistan	1
Totale	1.635

Nome	#
Le sindromi miasteniche congenite	250
Which are the factors influencing NIV adaptation and tolerance in ALS patients?	208
Effect of exercise on telomere length and telomere proteins expression in mdx mice	201
Amino acid sequence homology between thyroid autoantigens and central nervous system proteins: Implications for the steroid-responsive encephalopathy associated with autoimmune thyroiditis	175
MuSK-Associated Myasthenia Gravis: Clinical Features and Management	162
Severe congenital myasthenic syndrome associated with novel biallelic mutation of the CHRND gene	160
Endocrine myopathies: Clinical and histopathological features of the major forms	155
Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: A case report	131
Methotrexate as a steroid-sparing agent in myasthenia gravis: A preliminary retrospective study	127
Molecular analysis of SMARD1 patient-derived cells demonstrates that nonsense-mediated mRNA decay is impaired	86
null	21
Totale	1.676

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	60	0	0	0	0	1	0	9	5	1	15	3	26
2022/2023	205	15	25	9	14	8	19	0	8	96	0	7	4
2023/2024	71	4	12	3	5	9	11	5	2	1	9	6	4
2024/2025	294	9	6	2	18	17	8	25	55	59	40	26	29
2025/2026	857	54	51	45	51	70	154	128	117	99	45	16	27
2026/2027	119	15	26	31	45	2	0	0	0	0	0	0	0
Totale													1.676